Miroslawa Nowak
- Rheumatology top 5%
- Spondyloarthritis Studies and Treatments 10
- Rheumatoid Arthritis Research and Therapies 6
- Systemic Lupus Erythematosus Research 3
- Immunology top 10%
- Psoriasis: Treatment and Pathogenesis 12
- Hematology top 10%
- Autoimmune and Inflammatory Disorders Research 5
-
- Cytokine Signaling Pathways and Interactions 6
-
- Chronic Lymphocytic Leukemia Research 5
-
- Monoclonal and Polyclonal Antibodies Research 3
- Co-authors
- Philip J. MeaseGabor G. IlleiKazuki TakadaCheryl YarboroAlan KivitzJoseph BleibergBruce T. VolpeFrank Behrens
- Journals
- Annals of the Rheumatic Diseases (10 papers)Clinical Pharmacology & Therapeutics (1 paper)Lara D. Veeken (1 paper)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Miroslawa Nowak
23 papers receiving 519 citations
Hit Papers
Peers
Comparison fields: 5 of 64
- Rheumatology 311
- Immunology 260
- Biological Psychiatry 21
- Hematology 88
- Neurology 79
Countries citing papers authored by Miroslawa Nowak
This map shows the geographic impact of Miroslawa Nowak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miroslawa Nowak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miroslawa Nowak more than expected).
Fields of papers citing papers by Miroslawa Nowak
This network shows the impact of papers produced by Miroslawa Nowak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miroslawa Nowak. The network helps show where Miroslawa Nowak may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Miroslawa Nowak, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 6 | |
| 5 | 2023 | 6 | |
| 6 | Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritisbreakdown → | 2022 | 134 |
| 7 | 2022 | 5 | |
| 8 | 2022 | 1 | |
| 9 | 2021 | 1 | |
| 10 | 2021 | 3 | |
| 11 | 2020 | 28 | |
| 12 | 2020 | 12 | |
| 13 | 2020 | 19 | |
| 14 | 2019 | 2 | |
| 15 | 2017 | 26 | |
| 16 | 2014 | 3 | |
| 17 | 2013 | 1 | |
| 18 | 2006 | 190 | |
| 19 | 2006 | 58 | |
| 20 | 2004 | 15 |
About Miroslawa Nowak
Miroslawa Nowak is a scholar working on Rheumatology, Immunology and Hematology, having authored 23 papers that have together received 527 indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (12 papers), Spondyloarthritis Studies and Treatments (10 papers), Rheumatoid Arthritis Research and Therapies (6 papers), Cytokine Signaling Pathways and Interactions (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Autoimmune and Inflammatory Disorders Research (5 papers), Systemic Lupus Erythematosus Research (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Rheumatology (311 citations), Immunology (260 citations) and Biological Psychiatry (21 citations). Miroslawa Nowak has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Philip J. Mease, Gabor G. Illei, Kazuki Takada, Cheryl Yarboro, Alan Kivitz, Joseph Bleiberg, Bruce T. Volpe, Frank Behrens, Larissa Lapteva and Tresa Roebuck‐Spencer. Their work appears in journals such as Annals of the Rheumatic Diseases, Clinical Pharmacology & Therapeutics and Lara D. Veeken.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.